MEP56908A - Reconstitutable parenteral composition containing a cox-2 inhibitor - Google Patents

Reconstitutable parenteral composition containing a cox-2 inhibitor

Info

Publication number: MEP56908A
Authority: ME; Montenegro
Prior art keywords: composition; cox; weight; parenterally acceptable; inhibitor
Prior art date: 2001-04-03

Application number

MEP-569/08A

Other languages

Bosnian (bs)

English (en)

Croatian (hr)

Inventor

Tugrul T Kararli

Sandeep Nema

Aziz Karim

Original Assignee

Pharmacia Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-03

Filing date

2002-04-02

Publication date

2011-05-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23075770&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP56908(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-02 Application filed by Pharmacia Corp filed Critical Pharmacia Corp

2011-05-10 Publication of MEP56908A publication Critical patent/MEP56908A/xx

Links

239000000203 mixture Substances 0.000 title abstract 4
229940111134 coxibs Drugs 0.000 title 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title 1
239000003814 drug Substances 0.000 abstract 3
229940079593 drug Drugs 0.000 abstract 2
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 1
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract 1
229940124639 Selective inhibitor Drugs 0.000 abstract 1
239000006172 buffering agent Substances 0.000 abstract 1
239000004615 ingredient Substances 0.000 abstract 1
238000002347 injection Methods 0.000 abstract 1
239000007924 injection Substances 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
238000012792 lyophilization process Methods 0.000 abstract 1
229960003925 parecoxib sodium Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
239000000843 powder Substances 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000243 solution Substances 0.000 abstract 1
239000002904 solvent Substances 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
ICJGKYTXBRDUMV-UHFFFAOYSA-N trichloro(6-trichlorosilylhexyl)silane Chemical compound Cl[Si](Cl)(Cl)CCCCCC[Si](Cl)(Cl)Cl ICJGKYTXBRDUMV-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Furan Compounds (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Pyrane Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

MEP-569/08A 2001-04-03 2002-04-02 Reconstitutable parenteral composition containing a cox-2 inhibitor MEP56908A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28105801P	2001-04-03	2001-04-03
PCT/US2002/010252 WO2002080912A1 (en)	2001-04-03	2002-04-02	Reconstitutable parenteral composition containing a cox-2 inhibitor

Publications (1)

Publication Number	Publication Date
MEP56908A true MEP56908A (en)	2011-05-10

Family

ID=23075770

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-569/08A MEP56908A (en)	2001-04-03	2002-04-02	Reconstitutable parenteral composition containing a cox-2 inhibitor

Country Status (46)

Country	Link
US (1)	US7695736B2 (xx)
EP (1)	EP1372645B1 (xx)
JP (1)	JP4511792B2 (xx)
KR (1)	KR100980685B1 (xx)
CN (3)	CN1512882A (xx)
AP (1)	AP1776A (xx)
AR (1)	AR033688A1 (xx)
AT (1)	ATE310516T1 (xx)
AU (1)	AU2002256031B2 (xx)
BG (1)	BG66367B1 (xx)
BR (1)	BRPI0208652B8 (xx)
CA (1)	CA2442906C (xx)
CZ (1)	CZ299623B6 (xx)
DE (1)	DE60207535T2 (xx)
DK (1)	DK1372645T3 (xx)
EA (1)	EA006554B1 (xx)
EC (1)	ECSP034789A (xx)
EG (1)	EG24345A (xx)
ES (1)	ES2252448T3 (xx)
GE (1)	GEP20063775B (xx)
GT (1)	GT200200065A (xx)
HK (2)	HK1243338A1 (xx)
HR (1)	HRP20030793B1 (xx)
HU (1)	HU229264B1 (xx)
IL (2)	IL158209A0 (xx)
IS (1)	IS2408B (xx)
JO (1)	JO2337B1 (xx)
MA (1)	MA27008A1 (xx)
ME (1)	MEP56908A (xx)
MX (1)	MXPA03009013A (xx)
MY (1)	MY137736A (xx)
NO (1)	NO333381B1 (xx)
NZ (1)	NZ528547A (xx)
OA (1)	OA12498A (xx)
PA (1)	PA8542701A1 (xx)
PE (1)	PE20021017A1 (xx)
PL (1)	PL205658B1 (xx)
RS (1)	RS50430B (xx)
SI (1)	SI1372645T1 (xx)
SK (1)	SK287754B6 (xx)
SV (1)	SV2002000969A (xx)
TN (2)	TNSN02039A1 (xx)
TW (1)	TWI314867B (xx)
UA (1)	UA77173C2 (xx)
WO (1)	WO2002080912A1 (xx)
ZA (1)	ZA200307630B (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6929954B2 (en) *	2000-11-02	2005-08-16	Chromaceutical Advanced Technologies, Inc.	Method for producing purified hematinic iron-saccharidic complex and product produced
JP4369120B2 (ja) *	2000-11-02	2009-11-18	クロマシューティカル・アドヴァンスト・テクノロジーズ，インコーポレイテッド	精製された造血性鉄−サッカリド錯体の生成方法およびそれによって生成した生成物
KR20050044459A (ko) *	2001-11-13	2005-05-12	파마시아 코포레이션	파레콕시브 등의 설폰아미드 선구약물의 경구 투여 형태
US20030232871A1 (en) *	2002-03-15	2003-12-18	Sheikh Ahmad Y.	Crystalline parecoxib sodium
US7964568B2 (en) *	2003-05-30	2011-06-21	Chromaceutical Advanced Technologies, Inc.	Synthesis of high molecular weight iron-saccharidic complexes
DE10327674A1 (de) *	2003-06-20	2005-01-05	Awd.Pharma Gmbh & Co. Kg	Injizierbare Darreichungsform von Flupirtin
CN101217939A (zh) *	2005-05-27	2008-07-09	灵药生物技术有限公司	可注射组合物及制备这类组合物的方法
BRPI0711048A2 (pt) *	2006-05-09	2011-08-23	Astrazeneca Ab	formulações parenteral esterilizada e sólida estáveis, solução para administração parenteral, processos para a preparação de uma formulação e para a fabricação de um produto, método para prevenir ou tratar doenças gastrintestinais, uso de uma formulação sólida estável
WO2008029200A1 (en) *	2006-09-03	2008-03-13	Techfields Biochem Co. Ltd	Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
US20080279930A1 (en) *	2007-05-07	2008-11-13	Bernd Terhaag	Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
JP5563473B2 (ja) *	2007-11-29	2014-07-30	オールトランツインコーポレイティド	マイクロニードル孔バイアビリティを向上させるための方法及び組成物
KR100967490B1 (ko) *	2009-11-21	2010-07-07	곽철호	하수구의 배출 처리 구조
CN104080468A (zh)	2011-11-02	2014-10-01	哈尔西恩股份有限公司	用于创伤治疗的方法和组合物
WO2013096650A2 (en)	2011-12-23	2013-06-27	Pioneer Surgical Technology	Continuous matrix with osteoconductive particles dispersed therein, method of forming thereof, and method of regenerating bone therewith
CN102512383A (zh) *	2011-12-25	2012-06-27	天津市嵩锐医药科技有限公司	供注射用的帕瑞昔布钠药物组合物
CN104771370B (zh) *	2014-01-14	2020-07-24	南京圣和药业股份有限公司	帕瑞昔布钠冻干粉针剂及其制备方法
JP2017505349A (ja)	2014-02-11	2017-02-16	ドクターレディズラボラトリーズリミテッド	セレコキシブの非経口組成物
CN105726496B (zh) *	2014-12-12	2019-05-28	湖南科伦药物研究有限公司	一种帕瑞昔布钠冻干粉剂、其制备方法及其粉剂产品
CN105125506A (zh) *	2015-08-18	2015-12-09	上海秀新臣邦医药科技有限公司	一种注射用帕瑞昔布钠及其制备方法
CN105168152B (zh) *	2015-08-27	2018-06-01	上海华源药业（宁夏）沙赛制药有限公司	一种帕瑞昔布钠冻干粉及其制备方法
US10639340B2 (en)	2018-06-18	2020-05-05	Eric Young	Method of drying botanicals
US11243028B2 (en) *	2018-12-14	2022-02-08	Fortunata, LLC	Systems and methods of cryo-curing
MX2021010479A (es)	2019-03-01	2022-02-11	Eurofarma Laboratorios S A	Composicion farmaceutica liofilizada de antiinflamatorio no esteroideo.
CN110960493B (zh) *	2019-12-30	2022-03-11	山东罗欣药业集团股份有限公司	一种帕瑞昔布钠冻干制剂及其制备方法
CN113456597B (zh) *	2020-03-30	2023-02-14	石药集团欧意药业有限公司	一种注射用帕瑞昔布钠及其制备方法
CN116421569B (zh) *	2023-06-15	2023-09-05	四川尚锐生物医药有限公司	一种注射用帕瑞昔布钠药物组合物及其制备方法

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4434163A (en) *	1981-06-01	1984-02-28	Pfizer Inc.	Water-soluble benzothiazine dioxide salts
US4797388A (en) *	1984-05-21	1989-01-10	Cetus Corporation	Pharmaceutical compositions with galactitol as carrier
US4677195A (en) *	1985-01-11	1987-06-30	Genetics Institute, Inc.	Method for the purification of erythropoietin and erythropoietin compositions
US5036060A (en) *	1988-07-25	1991-07-30	Fujisawa Usa, Inc.	Cyclophosphamide
US5616458A (en)	1990-03-14	1997-04-01	Board Of Regents, University Of Tx System	Tripterygium wilfordii hook F extracts and components, and uses thereof
US5604260A (en)	1992-12-11	1997-02-18	Merck Frosst Canada Inc.	5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en)	1992-12-22	1996-08-06	Merck Frosst Canada, Inc.	Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
CA2152792C (en)	1993-01-15	2000-02-15	Stephen R. Bertenshaw	Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5380738A (en)	1993-05-21	1995-01-10	Monsanto Company	2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en)	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
US5436265A (en)	1993-11-12	1995-07-25	Merck Frosst Canada, Inc.	1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5593992A (en)	1993-07-16	1997-01-14	Smithkline Beecham Corporation	Compounds
US5344991A (en)	1993-10-29	1994-09-06	G.D. Searle & Co.	1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5434178A (en)	1993-11-30	1995-07-18	G.D. Searle & Co.	1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5475018A (en)	1993-11-30	1995-12-12	G. D. Searle & Co.	1,5-diphenyl pyrazole compounds for treatment of inflammation
US5466823A (en)	1993-11-30	1995-11-14	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides
US5401765A (en)	1993-11-30	1995-03-28	G. D. Searle	1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5393790A (en)	1994-02-10	1995-02-28	G.D. Searle & Co.	Substituted spiro compounds for the treatment of inflammation
US5418254A (en)	1994-05-04	1995-05-23	G. D. Searle & Co.	Substituted cyclopentadienyl compounds for the treatment of inflammation
WO1995030652A1 (en)	1994-05-04	1995-11-16	G.D. Searle & Co.	Substituted spirodienes for the treatment of inflammation
BE1008307A3 (fr)	1994-06-16	1996-04-02	Europharmaceuticals Sa	Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
US5486534A (en)	1994-07-21	1996-01-23	G. D. Searle & Co.	3,4-substituted pyrazoles for the treatment of inflammation
JPH10504542A (ja)	1994-07-27	1998-05-06	ジー．ディー．サールアンドカンパニー	炎症処置用の置換チアゾール化合物
US5620999A (en)	1994-07-28	1997-04-15	Weier; Richard M.	Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en)	1994-07-28	1997-04-01	Gd Searle & Co	1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en)	1994-08-29	1996-05-28	Merck Frosst Canada, Inc.	Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5420343A (en)	1994-08-31	1995-05-30	G. D. Searle & Co.	Derivatives of aromatic cyclic alkylethers
US5585504A (en)	1994-09-16	1996-12-17	Merck & Co., Inc.	Process of making cox-2 inhibitors having a lactone bridge
US5696143A (en)	1994-09-20	1997-12-09	Talley; John J.	Benz G! indazolyl derivatives for the treatment of inflammation
US5547975A (en)	1994-09-20	1996-08-20	Talley; John J.	Benzopyranopyrazolyl derivatives for the treatment of inflammation
JPH10507765A (ja)	1994-10-27	1998-07-28	メルクフロストカナダインコーポレーテツド	シクロオキシゲナーゼ−２阻害剤として有用なスチルベン誘導体
US5739166A (en)	1994-11-29	1998-04-14	G.D. Searle & Co.	Substituted terphenyl compounds for the treatment of inflammation
JP2636819B2 (ja)	1994-12-20	1997-07-30	日本たばこ産業株式会社	オキサゾール系複素環式芳香族化合物
JP3181190B2 (ja)	1994-12-20	2001-07-03	日本たばこ産業株式会社	オキサゾール誘導体
DE69529690T2 (de)	1994-12-21	2003-11-13	Merck Frosst Canada Inc	Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
US5552422A (en)	1995-01-11	1996-09-03	Merck Frosst Canada, Inc.	Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
CA2211320C (en)	1995-01-31	2007-03-20	Merck Frosst Canada Inc.	5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
US5596008A (en)	1995-02-10	1997-01-21	G. D. Searle & Co.	3,4-Diaryl substituted pyridines for the treatment of inflammation
US5686470A (en)	1995-02-10	1997-11-11	Weier; Richard M.	2, 3-substituted pyridines for the treatment of inflammation
US5633272A (en)	1995-02-13	1997-05-27	Talley; John J.	Substituted isoxazoles for the treatment of inflammation
JP3802581B2 (ja)	1995-03-01	2006-07-26	富山化学工業株式会社	新規なビフェニル誘導体またはその塩およびそれらを含有する抗炎症剤
TR199701105T1 (xx)	1995-04-04	1998-02-21	Glaxo Group Limited	�midazo (1,2-a)piridin t�revleri.
US5691374A (en)	1995-05-18	1997-11-25	Merck Frosst Canada Inc.	Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5639780A (en)	1995-05-22	1997-06-17	Merck Frosst Canada, Inc.	N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en)	1995-05-22	1996-04-23	Merck Frosst Canada, Inc.	N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5604253A (en)	1995-05-22	1997-02-18	Merck Frosst Canada, Inc.	N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
RO118200B1 (ro)	1995-05-25	2003-03-28	Gd Searle & Co Chicago	Procedeu pentru obtinerea (3-haloalchil-1h-pirazol-1-il)-arilsulfonamidelor
US5643933A (en)	1995-06-02	1997-07-01	G. D. Searle & Co.	Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5739143A (en)	1995-06-07	1998-04-14	Smithkline Beecham Corporation	Imidazole compounds and compositions
US5658903A (en)	1995-06-07	1997-08-19	Smithkline Beecham Corporation	Imidazole compounds, compositions and use
GB9514518D0 (en)	1995-07-15	1995-09-13	Sod Conseils Rech Applic	Guanidine salt inhibitors of NO synthase and cyclooxygenase
JPH0977664A (ja)	1995-09-13	1997-03-25	Yakult Honsha Co Ltd	シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
US5756529A (en)	1995-09-29	1998-05-26	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
US6020343A (en)	1995-10-13	2000-02-01	Merck Frosst Canada, Inc.	(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US5981576A (en)	1995-10-13	1999-11-09	Merck Frosst Canada, Inc.	(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6057319A (en)	1995-10-30	2000-05-02	Merck Frosst Canada & Co.	3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
ZA97175B (en)	1996-01-11	1997-11-04	Smithkline Beecham Corp	Novel substituted imidazole compounds.
US6046208A (en)	1996-01-11	2000-04-04	Smithkline Beecham Corporation	Substituted imidazole compounds
US5977103A (en)	1996-01-11	1999-11-02	Smithkline Beecham Corporation	Substituted imidazole compounds
US5746546A (en) *	1996-01-24	1998-05-05	Stabilizer, Inc.	Soil stabilization composition and method
US5789413A (en)	1996-02-01	1998-08-04	Merck Frosst Canada, Inc.	Alkylated styrenes as prodrugs to COX-2 inhibitors
GB9607503D0 (en)	1996-04-11	1996-06-12	Merck Frosst Canada Inc	Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
US5807873A (en)	1996-04-04	1998-09-15	Laboratories Upsa	Diarylmethylidenefuran derivatives and their uses in therapeutics
US5908858A (en)	1996-04-05	1999-06-01	Sankyo Company, Limited	1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
TR199802049T2 (xx) *	1996-04-12	1999-01-18	G.D.Searle & Co.	COX-2 Inhibit�rlerinin �nilac� olarak s�bstit�e edilmi� benzens�lfonamid t�revleri.
US5922742A (en)	1996-04-23	1999-07-13	Merck Frosst Canada	Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
US5883267A (en)	1996-05-31	1999-03-16	Merck & Co., Inc.	Process for making phenyl heterocycles useful as cox-2 inhibitors
WO1997046532A1 (en)	1996-06-03	1997-12-11	Boehringer Ingelheim Pharmaceuticals, Inc.	2-benzyl-4-sulfonyl-4h-isoquinolin-1,3-diones and their use as anti-inflammatory agents
US5677318A (en)	1996-07-11	1997-10-14	Merck Frosst Canada, Inc.	Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en)	1996-07-18	1999-01-19	Merck Frosst Canad, Inc.	Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5776967A (en)	1996-07-26	1998-07-07	American Home Products Corporation	Pyranoindole inhibitors of COX--2
FR2751964B1 (fr)	1996-08-01	1998-10-30	Union Pharma Scient Appl	Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2751966B1 (fr)	1996-08-01	1998-10-30	Union Pharma Scient Appl	Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
US5830911A (en)	1996-08-14	1998-11-03	American Home Products Corporation	Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US6005000A (en)	1996-08-22	1999-12-21	Oxis International, Inc.	5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
FR2753449B1 (fr)	1996-09-13	1998-12-04	Union Pharma Scient Appl	Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
US5972950A (en)	1996-10-08	1999-10-26	Laboratories Upsa	1,2-diarylmethylene derivatives, their methods of preparation and their uses in therapeutics
US5681842A (en)	1996-11-08	1997-10-28	Abbott Laboratories	Prostaglandin synthase-2 inhibitors
US5869524A (en)	1996-11-12	1999-02-09	American Home Products Corporation	Indene inhibitors of COX-2
US6096753A (en)	1996-12-05	2000-08-01	Amgen Inc.	Substituted pyrimidinone and pyridone compounds and methods of use
EP0846689B1 (en)	1996-12-09	2004-01-14	Pfizer Inc.	Benzimidazole compounds
PT946507E (pt)	1996-12-10	2004-02-27	Searle & Co	Compostos de pirrolilo substituidos para o tratamento da inflamacao
US5973191A (en)	1996-12-30	1999-10-26	Vanderbilt University	Selective inhibitors of prostaglandin endoperoxide synthase-2
US5929076A (en)	1997-01-10	1999-07-27	Smithkline Beecham Corporation	Cycloalkyl substituted imidazoles
US5783597A (en)	1997-03-04	1998-07-21	Ortho Pharmaceutical Corporation	2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
EP0863134A1 (en)	1997-03-07	1998-09-09	Merck Frosst Canada Inc.	2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6071954A (en)	1997-03-14	2000-06-06	Merk Frosst Canada, Inc.	(methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
US6004960A (en)	1997-03-14	1999-12-21	Merck Frosst Canada, Inc.	Pyridazinones as inhibitors of cyclooxygenase-2
US6034256A (en)	1997-04-21	2000-03-07	G.D. Searle & Co.	Substituted benzopyran derivatives for the treatment of inflammation
US6046217A (en)	1997-09-12	2000-04-04	Merck Frosst Canada & Co.	2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
RS49982B (sr) *	1997-09-17	2008-09-29	Euro-Celtique S.A.,	Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6040450A (en)	1997-09-25	2000-03-21	Merck & Co., Inc.	Process for making diaryl pyridines useful as cox-2-inhibitors
FR2769311B1 (fr)	1997-10-07	1999-12-24	Union Pharma Scient Appl	Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US6133292A (en)	1997-10-30	2000-10-17	Merck Frosst Canada & Co.	Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
US6020347A (en)	1997-11-18	2000-02-01	Merck & Co., Inc.	4-substituted-4-piperidine carboxamide derivatives
FR2771412B1 (fr)	1997-11-26	2000-04-28	Adir	Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2329193C (en)	1998-04-24	2007-01-23	Merck & Co., Inc.	Process for synthesizing cox-2 inhibitors
WO1999059583A1 (en) *	1998-05-18	1999-11-25	Merck & Co., Inc.	Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia
KR100295206B1 (ko) *	1998-08-22	2001-07-12	서경배	디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
US6277878B1 (en)	1998-09-07	2001-08-21	Pfizer Inc	Substituted indole compounds as anti-inflammatory and analgesic agents
US6077869A (en)	1998-10-29	2000-06-20	Ortho-Mcneil Pharmaceutical, Inc.	Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
US6077868A (en)	1999-07-20	2000-06-20	Wisconsin Alumni Research Foundation	Selective inhibition of cyclooxygenase-2
US6083969A (en)	1999-10-20	2000-07-04	Ortho-Mcneil Pharaceutical, Inc.	1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
ZA200206459B (en) *	2000-03-24	2003-08-13	Pharmacia Corp	Amidino compound and salts thereof useful as nitric oxide synthase inhibitors.
PE20020578A1 (es) *	2000-10-10	2002-08-14	Upjohn Co	Una composicion de antibiotico topico para el tratamiento de infecciones oculares

2002
- 2002-04-01 US US10/113,281 patent/US7695736B2/en not_active Expired - Lifetime
- 2002-04-01 MY MYPI20021178A patent/MY137736A/en unknown
- 2002-04-01 PE PE2002000258A patent/PE20021017A1/es active IP Right Grant
- 2002-04-02 WO PCT/US2002/010252 patent/WO2002080912A1/en active IP Right Grant
- 2002-04-02 RS YUP-858/03A patent/RS50430B/sr unknown
- 2002-04-02 HU HU0303750A patent/HU229264B1/hu unknown
- 2002-04-02 EP EP02725471A patent/EP1372645B1/en not_active Expired - Lifetime
- 2002-04-02 AU AU2002256031A patent/AU2002256031B2/en not_active Expired
- 2002-04-02 CZ CZ20032651A patent/CZ299623B6/cs not_active IP Right Cessation
- 2002-04-02 EA EA200301004A patent/EA006554B1/ru not_active IP Right Cessation
- 2002-04-02 AP APAP/P/2003/002879A patent/AP1776A/en active
- 2002-04-02 SK SK1228-2003A patent/SK287754B6/sk unknown
- 2002-04-02 DE DE60207535T patent/DE60207535T2/de not_active Expired - Lifetime
- 2002-04-02 IL IL15820902A patent/IL158209A0/xx unknown
- 2002-04-02 UA UA2003108945A patent/UA77173C2/xx unknown
- 2002-04-02 MX MXPA03009013A patent/MXPA03009013A/es active IP Right Grant
- 2002-04-02 CN CNA028107659A patent/CN1512882A/zh active Pending
- 2002-04-02 PL PL368597A patent/PL205658B1/pl unknown
- 2002-04-02 DK DK02725471T patent/DK1372645T3/da active
- 2002-04-02 CA CA002442906A patent/CA2442906C/en not_active Expired - Fee Related
- 2002-04-02 GE GE5312A patent/GEP20063775B/en unknown
- 2002-04-02 ES ES02725471T patent/ES2252448T3/es not_active Expired - Lifetime
- 2002-04-02 ME MEP-569/08A patent/MEP56908A/xx unknown
- 2002-04-02 JP JP2002578951A patent/JP4511792B2/ja not_active Expired - Lifetime
- 2002-04-02 CN CN201710474394.8A patent/CN107115302A/zh active Pending
- 2002-04-02 BR BRPI0208652A patent/BRPI0208652B8/pt not_active IP Right Cessation
- 2002-04-02 KR KR1020037013043A patent/KR100980685B1/ko active IP Right Grant
- 2002-04-02 SI SI200230231T patent/SI1372645T1/sl unknown
- 2002-04-02 AT AT02725471T patent/ATE310516T1/de active
- 2002-04-02 CN CN201710514915.8A patent/CN107213121A/zh active Pending
- 2002-04-02 OA OA1200300254A patent/OA12498A/en unknown
- 2002-04-02 NZ NZ528547A patent/NZ528547A/en not_active IP Right Cessation
- 2002-04-03 AR ARP020101224A patent/AR033688A1/es not_active Application Discontinuation
- 2002-04-03 EG EG2002040352A patent/EG24345A/xx active
- 2002-04-03 SV SV2002000969A patent/SV2002000969A/es active IP Right Grant
- 2002-04-03 PA PA20028542701A patent/PA8542701A1/es unknown
- 2002-04-03 GT GT200200065A patent/GT200200065A/es unknown
- 2002-04-03 TW TW091106757A patent/TWI314867B/zh not_active IP Right Cessation
- 2002-04-03 JO JO200231A patent/JO2337B1/en active
- 2002-04-03 TN TNTNSN02039A patent/TNSN02039A1/en unknown
2003
- 2003-07-08 TN TNPCT/US2002/010252A patent/TNSN03085A1/fr unknown
- 2003-09-30 ZA ZA200307630A patent/ZA200307630B/en unknown
- 2003-09-30 IS IS6972A patent/IS2408B/is unknown
- 2003-10-01 HR HRP20030793AA patent/HRP20030793B1/hr not_active IP Right Cessation
- 2003-10-01 IL IL158209A patent/IL158209A/en active IP Right Grant
- 2003-10-01 BG BG108221A patent/BG66367B1/bg unknown
- 2003-10-02 NO NO20034415A patent/NO333381B1/no not_active IP Right Cessation
- 2003-10-02 MA MA27332A patent/MA27008A1/fr unknown
- 2003-10-03 EC EC2003004789A patent/ECSP034789A/es unknown
2018
- 2018-02-28 HK HK18102864.9A patent/HK1243338A1/zh unknown
- 2018-03-27 HK HK18104186.6A patent/HK1244690A1/zh unknown

Also Published As

Publication number	Publication date
RS50430B (sr)	2009-12-31
EG24345A (en)	2009-02-11
ES2252448T3 (es)	2006-05-16
EP1372645A1 (en)	2004-01-02
US7695736B2 (en)	2010-04-13
TNSN03085A1 (fr)	2005-12-23
JP4511792B2 (ja)	2010-07-28
MY137736A (en)	2009-03-31
SK12282003A3 (sk)	2005-03-04
MA27008A1 (fr)	2004-12-20
AP1776A (en)	2007-08-28
JO2337B1 (en)	2006-06-28
CA2442906C (en)	2010-01-12
SV2002000969A (es)	2002-12-13
CN107213121A (zh)	2017-09-29
BG66367B1 (bg)	2013-10-31
AR033688A1 (es)	2004-01-07
KR20030087058A (ko)	2003-11-12
HUP0303750A3 (en)	2006-02-28
PL368597A1 (en)	2005-04-04
HK1244690A1 (zh)	2018-08-17
NO20034415D0 (no)	2003-10-02
AU2002256031B2 (en)	2006-05-18
HK1243338A1 (zh)	2018-07-13
GEP20063775B (en)	2006-03-27
EA006554B1 (ru)	2006-02-24
IS6972A (is)	2003-09-30
WO2002080912A1 (en)	2002-10-17
NO333381B1 (no)	2013-05-21
BG108221A (bg)	2010-08-31
US20030078266A1 (en)	2003-04-24
TNSN02039A1 (en)	2005-12-23
IL158209A0 (en)	2004-05-12
AP2003002879A0 (en)	2003-12-31
TWI314867B (en)	2009-09-21
HRP20030793A2 (en)	2005-10-31
KR100980685B1 (ko)	2010-09-07
GT200200065A (es)	2002-11-15
PE20021017A1 (es)	2002-11-24
DK1372645T3 (da)	2006-02-13
BR0208652B1 (pt)	2017-10-31
JP2004525949A (ja)	2004-08-26
IL158209A (en)	2010-05-31
MXPA03009013A (es)	2004-02-12
PA8542701A1 (es)	2002-10-28
NZ528547A (en)	2005-09-30
EP1372645B1 (en)	2005-11-23
DE60207535T2 (de)	2006-07-20
NO20034415L (no)	2003-12-02
DE60207535D1 (de)	2005-12-29
CN1512882A (zh)	2004-07-14
SI1372645T1 (sl)	2006-06-30
CZ299623B6 (cs)	2008-09-24
BR0208652A (pt)	2004-03-02
ECSP034789A (es)	2004-07-23
CZ20032651A3 (cs)	2004-07-14
OA12498A (en)	2006-05-24
BRPI0208652B8 (pt)	2021-05-25
PL205658B1 (pl)	2010-05-31
EA200301004A1 (ru)	2004-04-29
HRP20030793B1 (hr)	2013-05-31
IS2408B (is)	2008-09-15
ATE310516T1 (de)	2005-12-15
CN107115302A (zh)	2017-09-01
CA2442906A1 (en)	2002-10-17
YU85803A (sh)	2006-05-25
UA77173C2 (en)	2006-11-15
HU229264B1 (en)	2013-10-28
SK287754B6 (sk)	2011-08-04
HUP0303750A2 (hu)	2004-03-01
ZA200307630B (en)	2004-09-30

Publication	Publication Date	Title
MEP56908A (en)	2011-05-10	Reconstitutable parenteral composition containing a cox-2 inhibitor
PL378107A1 (pl)	2006-03-06	1,2,4-triazyny hamujące HIV
HUP0300565A3 (en)	2004-10-28	8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
MXPA02007942A (es)	2004-09-10	Derivados de pirrolopirimidinona, procesos de preparacion y uso.
BRPI0416743A (pt)	2007-01-16	formulação farmacêutica, e, métodos de preparar uma formulação de peptìdeo apropriada para uso em um dispositivo de injeção, para reduzir depósitos em equipamento de produção e no produto final, e para reduzir o entupimento de dispositivos de injeção por uma formulação de peptìdeo
SG10201901089TA (en)	2019-03-28	Novel lipids and compositions for the delivery of therapeutics
IL163831A (en)	2010-12-30	Derivatives of aminoindazoles, pharmaceutical compositions comprising them, process for their preparation and use thereof
ATE391708T1 (de)	2008-04-15	Verbindungen und gemische zur verabreichung eines aktiven agens
AR030857A1 (es)	2003-09-03	Derivados nitroso de difenolaminas, composiciones farmaceuticas que los contienen y su uso en la preparacion de productos medicinales
SG147450A1 (en)	2008-11-28	Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
TW200514772A (en)	2005-05-01	Novel tetrahydropyridine derivatives
NO20030897L (no)	2003-02-26	Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer
DE602004011966D1 (en)	2008-04-03	Heterocyclylverbindungen
PL1682528T3 (pl)	2008-01-31	Pochodne benzo[b][1,4]dioksepiny
NO304113B1 (no)	1998-10-26	Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
WO2006053089A3 (en)	2006-08-24	Methods and formulations for making pharmaceutical compositions containing bupropion
ATE346592T1 (de)	2006-12-15	Pharmazeutische zubereitungen mit einem cortisol synthese inhibitor
MY159418A (en)	2017-01-13	New derivatives of flavones, their preparation process, their use as medicaments, pharmaceutical compositions and new use
HRP20050466A2 (en)	2006-07-31	Pharmaceutical composition comprising a ltb4 antagonists and a cox-2 inhibitor or a combined cox 1/2 inhibitor
DK0817643T3 (da)	2007-07-30	Forbindelser og præparater til administration af aktive midler
FR2797446B1 (fr)	2001-11-02	Derives de phenanthroline-7-ones et leurs applications en therapeutique
TW200621314A (en)	2006-07-01	Methods and formulations for making pharmaceutical compositions containing bupropion